Human Reproductive Technologies: Products, Markets and Manufacturers

Table of Contents

• INTRODUCTION
  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR STUDY
  • SCOPE OF STUDY
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED BCC REPORTS
  • BCC ON-LINE SERVICES
  • DISCLAIMER
• SUMMARY
  • Summary Table: TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
  • Summary Figure: TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• INDUSTRY OVERVIEW
  • STRUCTURE AND FUNCTION OF THE REPRODUCTIVE SYSTEM
    • MALE
    • FEMALE
      • Female (Continued)
      • Female (Continued)
      • Female (Continued)
      • Neuroendocrine Regulation
      • Menarche
      • Menstruation Cycle
    • PHASES OF SEXUAL RESPONSES
  • Table 1 STRUCTURAL HOMOLOGUES OF THE MALE AND FEMALE REPRODUCTIVE SYSTEMS
    • Male Sexual Response
    • Female Sexual Response
    • NEUROHORMONAL CONTROL OF THE FEMALE AND MALE REPRODUCTIVE SYSTEM
      • Estrogen
      • Progestogens
      • Testosterone
    • EFFECTS OF AGING
      • Effects of Aging (Continued)
    • ISSUES AND TRENDS OF REPRODUCTIVE HEALTH
      • CONTRACEPTIVE INSURANCE
      • LEGISLATIVE ACTIONS
        • Bioethics Commission
          • Bioethics Commission (Continued)
      • NEW USE FOR CONTRACEPTIVES
        • New Use for Contraceptives (Continued)
      • AGING AND INFERTILITY
      • DEATH BY CONTRACEPTIVE PATCH
      • SEXUAL DYSFUNCTION AND CANCER
      • INFERTILITY AND CANCER
        • Chemotherapy
        • Radiation
        • Prevention Strategies
        • Procreative Alternatives
          • Procreative Alternatives (Continued)
      • MARKETING TACTICS
      • MERCHANDIZING TARGETING WOMEN
      • COUNTERFEIT PRODUCTS
      • GENERIC PARTICIPATION
  • Table 2 PRESCRIPTION GENERIC DRUG APPROVALS BY COMPANY AND APPROVAL DATE 2003-2004
    • INTERNATIONAL ISSUES
    • SURPLUS EMBRYOS AND FETUSES
      • Surplus Embryos and Fetuses (Continued)
    • DESIGNER BABIES
      • Designer Babies (Continued)
    • STEM CELL AND OTHER CONTROVERSIAL ISSUES
      • Stem Cell and Other Controversial Issues (Continued)
      • Stem Cell and Other Controversial Issues (Continued)
    • CONTROVERSIAL DISPOSAL OF EMBRYOS
      • Controversial Disposal of Embryos (Continued)
    • DEMOGRAPHICS
  • Table 3 U.S. LIVE BIRTH RATES, 1960-2004 (THOUSANDS)
  • Figure 1 U.S. LIVE BIRTH RATES, 1960-2004 (THOUSANDS)
  • Table 4 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2003-2030 (THOUSANDS)
  • Figure 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2003-2030
  • Table 5 CHARACTERISTICS OF WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR: 2000 AND ESTIMATED 2005
  • Table 6 WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR BY AGE AND LABOR FORCE STATUS: 1980 TO 2000
  • Table 7 ESTIMATED CONTRACEPTIVE USE BY TYPE BY AGE, ETHNIC GROUP AND MARITAL STATUS (%)
• INFERTILITY MARKET
  • INTRODUCTION AND OVERVIEW OF INFERTILITY
    • DEFINITION OF INFERTILITY
    • ETIOLOGY OF INFERTILITY
    • INCIDENCE AND PREVALENCE OF INFERTILITY
    • EVALUATION OF FERTILITY
      • Male Factor
        • Male Factor (Continued)
      • Artificial Insemination
        • Artificial Insemination (Continued)
        • Artificial Insemination (Continued)
      • Vaginal and Cervical Factors
      • Immunological Factors
      • Uterine and Tubal Factors
        • Uterine and Tubal Factors (Continued)
      • Ovarian Factors
    • UNEXPLAINED INFERTILITY
    • MULTIPLE BIRTHS
  • METHODS OF TREATMENT
    • FERTILITY PHARMACEUTICALS
      • Introduction and Types
        • Introduction and Types (Continued)
        • Antagon
        • Bravelle
        • Cetrotide
        • Clomid
          • Clomid (continued)
        • Crinone
        • Factrel
        • Fertinex
        • Follistim
        • Gonal-F
        • Humegon
        • Lupron
        • Novarel
        • Ovidrel
        • Parlodel
        • Pregnyl
        • Profasi
        • Prometrium
        • Repronex
        • Serophene
  • Table 8 PRESCRIPTION FERTILITY DRUGS
    • Market Revenues and Forecast
  • Table 9 MARKET SIZE OF U.S. INFERTILITY PHARMACEUTICALS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
    • Competitive Analysis
  • Table 10 INFERTILITY PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
  • Figure 3 INFERTILITY PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
    • Future Advancements in Infertility Products
  • Table 11 INFERTILITY DRUGS IN DEVELOPMENT
    • ARTIFICIAL REPRODUCTIVE TECHNOLOGIES
      • Types
        • IVF
          • Ovulation Induction
          • Oocyte Retrieval
          • Fertilization
          • Embryo Transfer
          • Results of IVF
        • GIFT
        • ZIFT
        • Wombs for Rent
        • Oocyte Donation
        • Frozen Embryos
      • U.S. Fertility Clinics
  • Table 12 2001 NATIONAL SUMMARY OF ARTIFICIAL REPRODUCTIVE THERAPIES
  • Table 13 2001 NATIONAL ARTIFICIAL REPRODUCTIVE THERAPIES CYCLE PROFILE
  • Table 14 2001 PREGNANCY SUCCESS RATES
    • Market Revenues and Forecast
  • Table 15 MARKET SIZE OF U.S. ARTIFICIAL REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
    • Future Trends in Artificial Reproductive Technology
      • Future Trends in Artificial (Continued)
      • Future Trends in Artificial (Continued)
    • FERTILITY DIAGNOSTICS
      • Types
        • Urine Studies
          • Pregnancy Testing
          • Ovulation Testing
          • Ovulation Testing (continued)
          • Sperm Testing
        • Hormone Studies
        • Blood Studies
      • Market Revenues and Forecast
  • Table 16 MARKET SIZE OF U.S. FERTILITY DIAGNOSTICS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
    • Competitive Analysis
  • Table 17 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
  • Figure 4 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
    • Future Advancements in Diagnostic Fertility Treatment
    • TOTAL INFERTILITY MARKET REVENUES AND FORECAST
  • Table 18 MARKET SIZE OF U.S. INFERTILITY TREATMENTS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
  • Figure 5 MARKET SIZE OF U.S. INFERTILITY TREATMENTS AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• CONTRACEPTION MARKET
  • INTRODUCTION AND OVERVIEW OF CONTRACEPTION
    • INTRODUCTION AND(CONTINUED)
  • Table 19 CONTRACEPTIVE EFFECTIVENESS: THEORETICAL AND ACTUAL USE RATES
    • METHODS OF TREATMENT
      • PHARMACEUTICALS
        • Types
          • Oral Contraceptives
            • Oral Contraceptives (continued)
            • Oral Contraceptives (continued)
            • Oral Contraceptives (continued)
  • Table 20 MOST COMMONLY USED ORAL CONTRACEPTIVES, 2004
    • Alesse
    • Brevicon and Norinyl
    • Desogen
    • Estrostep
    • Levlen ED
    • Levora
    • Loestrin
    • LoOvral
    • Low-Ogestrel
    • Microgestin
    • Mircette
    • Necon
    • Nordette
    • Nor-QD
    • OrthoEvra
    • Ortho Micronor
    • Ortho TriCyclen
    • OrthoCept
    • Ovcon 35
    • Ovral
    • Seasonale
    • Tri-Levlen
    • Tri-Norinyl
    • Triphasil
    • Trivora
    • Yasmin 28
    • Zovia
  • Table 21 ESTROGEN AND PROGESTIN HORMONE DOSES IN COMBINED BIRTH CONTROL PILLS
  • Table 21 (CONTINUED)
  • Table 22 PROGESTIN POTENCY OF DIFFERENT ORAL CONTRACEPTIVE PROGESTINS
  • Table 23 CURRENT PILL PROBLEMS AND CHOICE OF PILL TO SWITCH TO
    • Other Drug Regimens for Contraception
      • Other Drug Regimens for (continued)
    • Market Revenues and Forecast
  • Table 24 MARKET SIZE OF U.S. CONTRACEPTIVE PHARMACEUTICALS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
    • Competitive Analysis
  • Table 25 CONTRACEPTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ Millions)
  • Figure 6 CONTRACEPTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
    • DEVICES
      • Introduction and Types
        • Intrauterine Devices
        • NuvaRing
      • Market Revenues and Forecast
  • Table 26 MARKET SIZE OF U.S. CONTRACEPTIVE DEVICES AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
    • Competitive Analysis
  • Table 27 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
  • Figure 7 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
    • FUTURE ADVANCEMENTS IN CONTRACEPTION
  • Table 28 CONTRACEPTIVE DRUGS IN DEVELOPMENT
  • Table 28 (CONTINUED)
    • YASMIN 20
    • C31G (SAVVY)
    • IMPLANON
    • LIBREL
    • THE 7-DAY TRANSLUCENT CONTRACEPTIVE PATCH
    • TESTOSTERONE UNDECANOATE
    • IMMUNO-CONTRACEPTIVE VACCINE
    • ORG 33628
    • TANAPROGET
    • USHERCELL
    • INVISIBLE CONDOM
    • TOTAL MARKET REVENUES AND FORECAST
  • Table 29 MARKET SIZE OF U.S. CONTRACEPTIVE PRODUCTS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
  • Figure 8 MARKET SIZE OF U.S. CONTRACEPTIVE PRODUCTS AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• SEXUAL DYSFUNCTION MARKET
  • INTRODUCTION AND OVERVIEW
    • TYPES OF SEXUAL DYSFUNCTION
    • CAUSES OF SEXUAL DYSFUNCTION
    • DEMOGRAPHICS OF SEXUAL DYSFUNCTION
  • METHODS OF TREATMENT
    • PHARMACEUTICALS
      • Introduction and Types
        • Viagra
        • Cialis
        • Levitra
        • Uprima
        • Vasomax
        • Yohimbine
        • Caverject
        • MUSE
      • Market Revenues and Forecast
  • Table 30 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION PHARMACEUTICALS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
    • Competitive Analysis
  • Table 31 SEXUAL DYSFUNCTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
  • Figure 9 SEXUAL DYSFUNCTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
    • DEVICES
      • Introduction and Types
        • V.E.T. System and Assist
        • Erectaid Classic System
        • Imaging Agents
      • Market Revenues and Forecast
  • Table 32 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION DEVICES AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
    • Competitive Analysis
  • Table 33 SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
  • Figure 10 SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
    • FUTURE ADVANCEMENTS IN SEXUAL DYSFUNCTION
      • FUTURE ADVANCEMENTS IN(CONTINUED)
  • Table 34 SEXUAL DYSFUNCTION DRUGS IN DEVELOPMENT
  • Table 34 (CONTINUED)
    • ALPROX-TD
    • INTRINSA
    • ABT-724
    • ALISTA
    • TESTOSTERONE MDTS
    • APOMORPHINE
    • FEMPROX
    • LIBIGEL
    • PT-141
    • TA-1970
    • TESTOSTERONE VAGINAL RING
    • TOPIGLAN
    • TOSTRELLE
    • TOTAL MARKET REVENUES AND FORECAST
  • Table 35 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION TREATMENTS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
  • Figure 11 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION TREATMENTS AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• PATENTS
  • PATENT ANALYSIS BY MANUFACTURER
  • Table 36 SELECTED MANUFACTURER PATENTS FOR REPRODUCTIVE PRODUCTS AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT
    • PATENTS BY APPLICATION
      • INFERTILITY TREATMENTS
      • CONTRACEPTION
      • SEXUAL DYSFUNCTION
    • LEADING MARKET MANUFACTURERS
  • Table 37 PATENT ANALYSIS BY SELECTED LEADING REPRODUCTIVE TREATMENT MANUFACTURERS, 1976-PRESENT
• TOTAL MARKET
  • TOTAL MARKET SIZE BY CATEGORY
  • Table 38 TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
  • Figure 12 TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
  • Table 39 TOTAL REVENUES, MARKET SHARE, AND NUMBER OF MANUFACTURERS OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY MARKET SEGMENT, 2004 ($ MILLIONS)
  • Figure 13 NUMBER OF SELECTED MANUFACTURERS BY MARKET SEGMENT, 2004 (%)
  • Figure 14 U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET SHARE BY MARKET SEGMENT, 2004 (%)
    • INDUSTRY PARTICIPANTS BY CATEGORY
  • Table 40 REPRODUCTIVE INDUSTRY PARTICIPANTS BY PRODUCT CATEGORY
  • Table 40 (CONTINUED)
    • TOTAL MARKET SIZE BY PRODUCT TYPE
  • Table 41 TOTAL REVENUES OF U.S. REPRODUCTION PRODUCTS BY TYPE AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
  • Figure 15 TOTAL REVENUES OF U.S. REPRODUCTION PRODUCTS BY TYPE AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• APPENDIX
  • SELECTED LIST OF US FERTILITY CLINICS
    • ALABAMA
    • ARIZONA
    • CALIFORNIA
    • COLORADO
    • CONNECTICUT
    • DISTRICT OF COLUMBIA
    • FLORIDA
    • GEORGIA
    • IDAHO
    • ILLINOIS
    • INDIANA
    • KANSAS
    • MAINE
    • MARYLAND
    • MASSACHUSETTS
    • MICHIGAN
    • MINNESOTA
    • MONTANA
    • NEVADA
    • NEW HAMPSHIRE
    • NEW JERSEY
    • NEW YORK
    • NORTH CAROLINA
    • OREGON
    • RHODE ISLAND
    • SOUTH CAROLINA
    • SOUTH DAKOTA
    • TEXAS
    • VIRGINIA
    • UTAH
    • WASHINGTON
  • COMPANY PROFILES
    • BAYER AG
    • BERLEX LABORATORIES, INC.
    • BRISTOL-MYERS SQUIBB CO.
    • CHURCH & DWIGHT COMPANY, INC.
    • ELI LILLY & CO.
    • ENDOCARE, INC.
    • GLAXOSMITHKLINE PLC
    • ICOS CORP.
    • NOVARTIS INTERNATIONAL AG
    • ORGANON INTERNATIONAL, INC.
    • ORTHO-MCNEIL PHARMACEUTICAL, INC.
    • PFIZER, INC.
    • PRINCETON BIOMEDITECH CORP.
    • SERONO S.A.
    • TAP PHARMACEUTICAL PRODUCTS, INC.
    • VIVUS, INC.
    • WATSON PHARMACEUTICALS, INC.
    • WYETH
  • LIST OF COMPANIES
  • Table 42 LIST OF COMPANIES
  • Table 42 (CONTINUED)
  • Table 42 (CONTINUED)
  • Table 42 (CONTINUED)
  • Table 42 (CONTINUED)
  • Table 42 (CONTINUED)
  • Table 42 (CONTINUED)
• Summary Table:
• Table 1 STRUCTURAL HOMOLOGUES OF THE MALE AND FEMALE REPRODUCTIVE SYSTEMS
• Table 2 PRESCRIPTION GENERIC DRUG APPROVALS BY COMPANY AND APPROVAL DATE 2003-2004
• Table 3 U.S. LIVE BIRTH RATES, 1960-2004 (THOUSANDS)
• Table 4 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2003-2030 (THOUSANDS)
• Table 5 CHARACTERISTICS OF WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR: 2000 AND ESTIMATED 2005
• Table 6 WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR BY AGE AND LABOR FORCE STATUS: 1980 TO 2000
• Table 7 ESTIMATED CONTRACEPTIVE USE BY TYPE BY AGE, ETHNIC GROUP AND MARITAL STATUS (%)
• Table 8 PRESCRIPTION FERTILITY DRUGS
• Table 9 MARKET SIZE OF U.S. INFERTILITY PHARMACEUTICALS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 10 INFERTILITY PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
• Table 11 INFERTILITY DRUGS IN DEVELOPMENT
• Table 12 2001 NATIONAL SUMMARY OF ARTIFICIAL REPRODUCTIVE THERAPIES
• Table 13 2001 NATIONAL ARTIFICIAL REPRODUCTIVE THERAPIES CYCLE PROFILE
• Table 14 2001 PREGNANCY SUCCESS RATES
• Table 15 MARKET SIZE OF U.S. ARTIFICIAL REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 16 MARKET SIZE OF U.S. FERTILITY DIAGNOSTICS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 17 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
• Table 18 MARKET SIZE OF U.S. INFERTILITY TREATMENTS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 19 CONTRACEPTIVE EFFECTIVENESS: THEORETICAL AND ACTUAL USE RATES
• Table 20 MOST COMMONLY USED ORAL CONTRACEPTIVES, 2004
• Table 21 ESTROGEN AND PROGESTIN HORMONE DOSES IN COMBINED BIRTH CONTROL PILLS
• Table 22 PROGESTIN POTENCY OF DIFFERENT ORAL CONTRACEPTIVE PROGESTINS
• Table 23 CURRENT PILL PROBLEMS AND CHOICE OF PILL TO SWITCH TO
• Table 24 MARKET SIZE OF U.S. CONTRACEPTIVE PHARMACEUTICALS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 25 CONTRACEPTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ Millions)
• Table 26 MARKET SIZE OF U.S. CONTRACEPTIVE DEVICES AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 27 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
• Table 28 CONTRACEPTIVE DRUGS IN DEVELOPMENT
• Table 29 MARKET SIZE OF U.S. CONTRACEPTIVE PRODUCTS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 30 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION PHARMACEUTICALS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 31 SEXUAL DYSFUNCTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
• Table 32 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION DEVICES AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 33 SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
• Table 34 SEXUAL DYSFUNCTION DRUGS IN DEVELOPMENT
• Table 35 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION TREATMENTS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 36 SELECTED MANUFACTURER PATENTS FOR REPRODUCTIVE PRODUCTS AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT
• Table 37 PATENT ANALYSIS BY SELECTED LEADING REPRODUCTIVE TREATMENT MANUFACTURERS, 1976-PRESENT
• Table 38 TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 39 TOTAL REVENUES, MARKET SHARE, AND NUMBER OF MANUFACTURERS OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY MARKET SEGMENT, 2004 ($ MILLIONS)
• Table 40 REPRODUCTIVE INDUSTRY PARTICIPANTS BY PRODUCT CATEGORY
• Table 41 TOTAL REVENUES OF U.S. REPRODUCTION PRODUCTS BY TYPE AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 42 LIST OF COMPANIES
• Summary Figure:
• Figure 1 U.S. LIVE BIRTH RATES, 1960-2004 (THOUSANDS)
• Figure 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2003-2030
• Figure 3 INFERTILITY PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
• Figure 4 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
• Figure 5 MARKET SIZE OF U.S. INFERTILITY TREATMENTS AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• Figure 6 CONTRACEPTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
• Figure 7 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
• Figure 8 MARKET SIZE OF U.S. CONTRACEPTIVE PRODUCTS AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• Figure 9 SEXUAL DYSFUNCTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
• Figure 10 SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
• Figure 11 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION TREATMENTS AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• Figure 12 TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• Figure 13 NUMBER OF SELECTED MANUFACTURERS BY MARKET SEGMENT, 2004 (%)
• Figure 14 U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET SHARE BY MARKET SEGMENT, 2004 (%)
• Figure 15 TOTAL REVENUES OF U.S. REPRODUCTION PRODUCTS BY TYPE AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)